Notificação de entrada na fase nacional - PCT
#1.3
08/27/2024
RPI 2799
Application data
Number
112024010058Type
Filing
Publication
PCT
IB2022061716 The application was filed at the INPI on 12/02/2022. It awaits formal examination and publication in the RPI gazette.
Latest action published by the INPI: 08/27/2024. We update with every new RPI gazette, published weekly.
Applicants
ARRAY BIOPHARMA INC.
US
Inventors
C. C. (pessoa física)
US
IPC Classification
Priority claims
US
63/287,127 · 12/08/2021
US
63/393,043 · 07/28/2022
Abstract
FORMA CRISTALINA DE N-(2-CLORO-3-((5- CLORO-3-METIL-4-OXO-3,4-DI-HIDROQUINAZOLIN-6-IL)AMINO)-4- FLUOROFENIL)-3-FLUOROAZETIDINA-1-SULFONAMIDA. A presente invenção refere-se a uma forma cristalina de N-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-di-hidroquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfonamida, composições farmacêuticas compreendendo a referida forma cristalina, e métodos de uso da referida forma cristalina no tratamento de doenças e distúrbios associados à BRAF, tais como tumores associados à BRAF.
Publications in the Brazilian Industrial Property Gazette (RPI).
#1.3
08/27/2024
RPI 2799
#1.1
05/28/2024
RPI 2786
From the same holder
Same category
Patent monitoring
Receive alerts on INPI events, decisions, and expiry dates for your portfolio.